MBX Biosciences announced positive top-line phase 2 data for canvuparatide in chronic hypoparathyroidism, meeting its primary endpoint and demonstrating significant improvements in adults. The once-weekly injectable positions MBX to challenge established treatments such as Ascendis Pharma’s Yorvipath. Plans are underway to advance canvuparatide into phase 3 trials next year, marking a competitive new entrant in rare endocrine disorder therapies.